<DOC>
	<DOCNO>NCT01649635</DOCNO>
	<brief_summary>Primary Objective : - To assess effectiveness prophylactic treatment hematological complication ( grade ≥ 3 neutropenia ) result cabazitaxel treatment 21 day treatment initiation . Secondary Objectives : - PSA response rate ; - Descriptive assessment CTC ( circulate Tumor Cells ) ; - Rates grade ≥ 3 neutropenia febrile neutropenia grade ≥3 diarrhea treatment period ; - Description Health Quality Life patient ; - Incidence adverse event .</brief_summary>
	<brief_title>Study Cabazitaxel Combined With Prednisone Prophylaxis Neutropenia Complications Treatment Patients With Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>Screening : 15 day Treatment : disease progression Post-treatment Follow-up : 12 month</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion criterion : Histologically prove CastrationResistant Prostate Cancer ( stage IV ) ; Prior failure treatment docetaxel ; Documentation metastasis imaging . Performance status 0 1 ; Exclusion criterion : Previous treatment chemotherapy , except docetaxel ; Previous use abiraterone ; Inability maintain treatment androgen deprivation previous history orchiectomy ; Presence active malignancy history tumor diagnose last 5 year , except basal cell squamous cell carcinoma skin situ carcinoma skin , bladder anal canal ( tumor prevent participation treat , even last 5 year ) ; Hypersensitivity know allergy treatment study , include history severe hypersensitivity reaction ( ≥grade 3 ) docetaxel and/or polysorbate 80 contain drug History congestive heart failure myocardial infarction within last 6 month , uncontrolled cardiac arrhythmia , angina pectoris uncontrolled hypertension ; Uncontrolled severe illness medical condition ( include uncontrolled diabetes mellitus ) Presence severe comorbidity , opinion investigator , put patient risk impairs compliance protocol ; Known seropositivity HIV ; Presence significant psychiatric neurological disease , investigator 's opinion ; Presence uncontrolled hypercalcemia ; Refusal use appropriate contraception study period ; Participation clinical trial last 12 month , unless benefit patient justify principal investigator Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 Inadequate organ bone marrow function The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>